Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry.
A HPLC-tandem mass spectrometry method was developed and validated for the quantitation of intact oxaliplatin in human plasma. Plasma ultrafiltrates were precipitated with acetonitrile and separation was performed on a 250 mm Beckman ODS reverse phase column using a gradient mobile phase. The mass spectrometer was operated in positive ionization mode using TurboionSpray and precursor-product ion combinations of m/z 391.1-->305.1 and 371.1-->247.0 were monitored for oxaliplatin and carboplatin, the internal standard, respectively. The lower limit of quantitation for oxaliplatin was 20 ng/ml. The linear range of the method was 20-1000 ng/ml. The between- and within-day relative standard deviations ranged from 3.1 to 7.7%, and accuracy was within 5%. This method was successfully applied in a clinical study of oxaliplatin.
Zhang
Wenjiang
W
Department of Applied Molecular Oncology, Ontario Cancer Institute, Toronto, Canada.
Seymour
Lesley
L
Chen
Eric X
EX
D000970:Antineoplastic Agents / Q000097:blood* / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D009944:Organoplatinum Compounds / Q000097:blood* / Q000493:pharmacokinetics; D000077150:Oxaliplatin; D010949:Plasma / Q000737:chemistry*; D015203:Reproducibility of Results; D053719:Tandem Mass Spectrometry / Q000379:methods*; D014462:Ultrafiltration
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin